Logo image of AVGR

Avinger Inc (AVGR) Stock Fundamental Analysis

NASDAQ:AVGR - Nasdaq - US0537348775 - Common Stock - Currency: USD

0.474  -0.12 (-20.74%)

After market: 0.57 +0.1 (+20.25%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AVGR. AVGR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While AVGR seems to be doing ok healthwise, there are quite some concerns on its profitability. AVGR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

AVGR had negative earnings in the past year.
In the past year AVGR has reported a negative cash flow from operations.
AVGR had negative earnings in each of the past 5 years.
In the past 5 years AVGR always reported negative operating cash flow.
AVGR Yearly Net Income VS EBIT VS OCF VS FCFAVGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of AVGR (-127.59%) is worse than 89.89% of its industry peers.
AVGR has a Return On Equity of -447.82%. This is amonst the worse of the industry: AVGR underperforms 86.70% of its industry peers.
Industry RankSector Rank
ROA -127.59%
ROE -447.82%
ROIC N/A
ROA(3y)-106.27%
ROA(5y)-96.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVGR Yearly ROA, ROE, ROICAVGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

With a Gross Margin value of 20.94%, AVGR is not doing good in the industry: 80.32% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of AVGR has grown nicely.
AVGR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.35%
GM growth 5Y8.48%
AVGR Yearly Profit, Operating, Gross MarginsAVGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

4

2. Health

2.1 Basic Checks

AVGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVGR has more shares outstanding
AVGR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AVGR is higher compared to a year ago.
AVGR Yearly Shares OutstandingAVGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
AVGR Yearly Total Debt VS Total AssetsAVGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -48.14, we must say that AVGR is in the distress zone and has some risk of bankruptcy.
AVGR has a worse Altman-Z score (-48.14) than 91.49% of its industry peers.
AVGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.14
ROIC/WACCN/A
WACC5.15%
AVGR Yearly LT Debt VS Equity VS FCFAVGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 1.21 indicates that AVGR should not have too much problems paying its short term obligations.
AVGR has a worse Current ratio (1.21) than 84.57% of its industry peers.
A Quick Ratio of 0.81 indicates that AVGR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.81, AVGR is doing worse than 88.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.81
AVGR Yearly Current Assets VS Current LiabilitesAVGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.40% over the past year.
The Revenue has decreased by -6.30% in the past year.
Measured over the past years, AVGR shows a decrease in Revenue. The Revenue has been decreasing by -0.69% on average per year.
EPS 1Y (TTM)66.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.67%
Revenue 1Y (TTM)-6.3%
Revenue growth 3Y-4.41%
Revenue growth 5Y-0.69%
Sales Q2Q%-9.19%

3.2 Future

The Earnings Per Share is expected to grow by 21.51% on average over the next years. This is a very strong growth
AVGR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.27% yearly.
EPS Next Y-30.64%
EPS Next 2Y29.28%
EPS Next 3Y21.51%
EPS Next 5YN/A
Revenue Next Year-12.9%
Revenue Next 2Y29.82%
Revenue Next 3Y29.14%
Revenue Next 5Y27.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVGR Yearly Revenue VS EstimatesAVGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
AVGR Yearly EPS VS EstimatesAVGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 -100K -200K -300K -400K -500K

1

4. Valuation

4.1 Price/Earnings Ratio

AVGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVGR Price Earnings VS Forward Price EarningsAVGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVGR Per share dataAVGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

AVGR's earnings are expected to grow with 21.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.28%
EPS Next 3Y21.51%

0

5. Dividend

5.1 Amount

No dividends for AVGR!.
Industry RankSector Rank
Dividend Yield N/A

Avinger Inc

NASDAQ:AVGR (2/14/2025, 8:21:08 PM)

After market: 0.57 +0.1 (+20.25%)

0.474

-0.12 (-20.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-18 2025-03-18/amc
Inst Owners1.73%
Inst Owner Change0%
Ins Owners1.18%
Ins Owner Change-0.43%
Market Cap1.57M
Analysts82.86
Price Target5.1 (975.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-265.43%
Min EPS beat(2)-542.96%
Max EPS beat(2)12.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.05%
Min Revenue beat(2)-29.02%
Max Revenue beat(2)-1.08%
Revenue beat(4)0
Avg Revenue beat(4)-19.68%
Min Revenue beat(4)-29.02%
Max Revenue beat(4)-1.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-11.03
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-4.4
FCFYN/A
OCF(TTM)-4.4
OCFYN/A
SpS2.19
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.59%
ROE -447.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.94%
FCFM N/A
ROA(3y)-106.27%
ROA(5y)-96.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.35%
GM growth 5Y8.48%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.62%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.81
Altman-Z -48.14
F-Score4
WACC5.15%
ROIC/WACCN/A
Cap/Depr(3y)10.71%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.67%
EPS Next Y-30.64%
EPS Next 2Y29.28%
EPS Next 3Y21.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.3%
Revenue growth 3Y-4.41%
Revenue growth 5Y-0.69%
Sales Q2Q%-9.19%
Revenue Next Year-12.9%
Revenue Next 2Y29.82%
Revenue Next 3Y29.14%
Revenue Next 5Y27.27%
EBIT growth 1Y-10.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.16%
OCF growth 3YN/A
OCF growth 5YN/A